J&J's Weldon to get $143M in retirement

William C. Weldon, who oversaw Johnson & Johnson ($JNJ) during some of its most troubled years, will receive $143.5 million in retirement and deferred compensation after he relinquishes the CEO position, Bloomberg reports. In the last few years, J&J has had a raft of manufacturing problems at McNeil Consumer Health that led to the closing of a plant and the recall of products such as Tylenol. It has faced recalls and litigation over is hip implant products and a scandal over the marketing of its schizophrenia drug Risperdal. Just this week, reports said the Department of Justice had turned down a $1.3 billion settlement offer from J&J for its Risperdal problems because it wasn't enough. Story
 

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.